BTIG Initiates Coverage On Xtant Medical Hldgs with Buy Rating, Announces Price Target of $2
Portfolio Pulse from Benzinga Newsdesk
BTIG analyst Ryan Zimmerman has initiated coverage on Xtant Medical Holdings (AMEX:XTNT) with a Buy rating and set a price target of $2 for the company's stock.
December 05, 2023 | 1:40 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Xtant Medical Holdings received a Buy rating from BTIG analyst Ryan Zimmerman, with a price target of $2, indicating a positive outlook for the stock.
The initiation of coverage by an analyst with a Buy rating typically suggests a positive outlook on the stock, which can lead to increased investor interest and potentially drive the stock price up in the short term. The price target of $2 also suggests a significant upside from current levels, assuming the stock is currently trading below that price.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100